SCHEMBL10091908

SCHEMBL10091908

CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3c(Nc4cccc(NC(=O)c5ccc(CN6CCN(C)CC6)cc5)c4)cccc32)c1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.54
PRKAA1 Q13131 12/20 0.53
KDR P35968 11/20 0.53
PRKAA2 P54646 10/20 0.53
PDGFRB P09619 5/20 0.53
FGFR1 P11362 4/20 0.53
EGFR P00533 3/20 0.52
KIT P10721 2/20 0.52
NEK2 P51955 2/20 0.52
MELK Q14680 2/20 0.52
NTRK2 Q16620 3/20 0.51
RET P07949 3/20 0.51
GRK5 P34947 3/20 0.51
PLK4 O00444 2/20 0.51
DCLK1 O15075 2/20 0.51
PDPK1 O15530 2/20 0.51
DAPK3 O43293 2/20 0.51
ROCK2 O75116 2/20 0.51
RPS6KA5 O75582 2/20 0.51
RPS6KA4 O75676 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL397630 1.00 FLT3 (0.54) FLT3PRKAA1KDRPRKAA2PDGFRB
SCHEMBL397241 0.94 NTRK2 (0.56) FLT3PRKAA1KDRPRKAA2PDGFRB
SCHEMBL10091909 0.94 NTRK2 (0.56) FLT3PRKAA1KDRPRKAA2PDGFRB
SCHEMBL394152 0.91 PDGFRB (0.54) FLT3PRKAA1KDRPRKAA2PDGFRB
SCHEMBL10091910 0.91 PDGFRB (0.54) FLT3PRKAA1KDRPRKAA2PDGFRB
SCHEMBL4128689 0.89 RET (0.55) FLT3KDRPDGFRBFGFR1KIT
SCHEMBL4128697 0.89 RET (0.55) FLT3KDRPDGFRBFGFR1KIT
SCHEMBL395938 0.88 CSF1R (0.63) FLT3PRKAA1KDRPRKAA2PDGFRB
SCHEMBL10091878 0.88 CSF1R (0.63) FLT3PRKAA1KDRPRKAA2PDGFRB
SCHEMBL10091906 0.88 KDR (0.64) FLT3PRKAA1KDRPRKAA2PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 US disclosed
US-20080221192-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221192-A1 Compounds and Compositions as Protein Kinase Inhibitors BMX, FRK, PTK2B FLT3 93/4885PRKAA1 237/4885KDR 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.